Information Provided By:
Fly News Breaks for February 14, 2018
SGEN
Feb 14, 2018 | 06:49 EDT
JPMorgan analyst Cory Kasimov upgraded Seattle Genetics to Overweight and raised his price target for the shares to $66 from $60. The analyst sees a "compelling opportunity" for the company from a solid launch for Adcetris in frontline Hodgkin Lymphoma as well as another Phase 3 data set for mature T-cell lymphoma. The analyst is encouraged by the "significant steps" Seattle Genetics has taken to broaden its pipeline beyond Adcetris. He likes the stock's risk/reward at current share levels.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.